Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J, Grandits M, Palhares LCGF, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth AM, Sow HS, Chiaruttini G, Gilbert AE, Dodev T, Koers A, Pellizzari G, Ilieva KM, Man F, Ali N, Hobbs C, Lombardi S, Lionarons DA, Gould HJ, Beavil AJ, Geh JLC, MacKenzie Ross AD, Healy C, Calonje E, Downward J, Nestle FO, Tsoka S, Josephs DH, Blower PJ, Karagiannis P, Lacy KE, Spicer J, Karagiannis SN, Bax HJ. Chauhan J, et al. Among authors: sow hs. Nat Commun. 2023 Apr 25;14(1):2192. doi: 10.1038/s41467-023-37811-3. Nat Commun. 2023. PMID: 37185332 Free PMC article.
AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.
Ilieva KM, Fazekas-Singer J, Bax HJ, Crescioli S, Montero-Morales L, Mele S, Sow HS, Stavraka C, Josephs DH, Spicer JF, Steinkellner H, Jensen-Jarolim E, Tutt ANJ, Karagiannis SN. Ilieva KM, et al. Among authors: sow hs. Allergy. 2019 Oct;74(10):1985-1989. doi: 10.1111/all.13818. Epub 2019 May 27. Allergy. 2019. PMID: 30964550 Free PMC article. No abstract available.
IgE Antibodies against Cancer: Efficacy and Safety.
Chauhan J, McCraw AJ, Nakamura M, Osborn G, Sow HS, Cox VF, Stavraka C, Josephs DH, Spicer JF, Karagiannis SN, Bax HJ. Chauhan J, et al. Among authors: sow hs. Antibodies (Basel). 2020 Oct 16;9(4):55. doi: 10.3390/antib9040055. Antibodies (Basel). 2020. PMID: 33081206 Free PMC article. Review.
CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
Cheung A, Chenoweth AM, Quist J, Sow HS, Malaktou C, Ferro R, Hoffmann RM, Osborn G, Sachouli E, French E, Marlow R, Lacy KE, Papa S, Grigoriadis A, Karagiannis SN. Cheung A, et al. Among authors: sow hs. Cancers (Basel). 2022 Jul 11;14(14):3361. doi: 10.3390/cancers14143361. Cancers (Basel). 2022. PMID: 35884422 Free PMC article.
FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS. Sow HS, et al. Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12. Int J Cancer. 2019. PMID: 30259976 Free article.
11 results